| Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with card. |
businesswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after th. |
businesswire.com |
2025-05-05 14:00:00 |
Czytaj oryginał (ang.) |
| Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y |
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales. |
zacks.com |
2025-05-02 15:55:36 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript |
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan Stanley Operator Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode. |
seekingalpha.com |
2025-05-01 17:11:27 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 15:35:37 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates |
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2025-05-01 14:20:39 |
Czytaj oryginał (ang.) |
| Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics |
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-04-29 14:21:04 |
Czytaj oryginał (ang.) |
| Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly. |
businesswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline |
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:10 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the. |
businesswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? |
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-10 14:35:54 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. |
businesswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois. |
businesswire.com |
2025-03-29 15:00:00 |
Czytaj oryginał (ang.) |
| FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds. |
businesswire.com |
2025-03-28 18:44:00 |
Czytaj oryginał (ang.) |
| siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials |
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering. |
globenewswire.com |
2025-03-28 09:14:00 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock |
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran). |
benzinga.com |
2025-03-24 16:08:47 |
Czytaj oryginał (ang.) |
| Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? |
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-03-24 13:00:26 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster |
Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. |
seekingalpha.com |
2025-03-21 19:37:36 |
Czytaj oryginał (ang.) |
| Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy |
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. |
zacks.com |
2025-03-21 15:50:27 |
Czytaj oryginał (ang.) |
| Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps |
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. |
benzinga.com |
2025-03-21 12:00:24 |
Czytaj oryginał (ang.) |
| Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent blockbuster opportunities as its pipeline rapidly expands across multiple therapeutic areas. “Alnylam is driving the fi. |
businesswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y |
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales. |
zacks.com |
2025-02-14 12:01:40 |
Czytaj oryginał (ang.) |
| Alnylam: Waiting For Regulatory Updates In March |
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows. |
seekingalpha.com |
2025-02-13 19:01:04 |
Czytaj oryginał (ang.) |
| Alnylam Delivers a Big Q4 Earnings Beat |
Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share. |
fool.com |
2025-02-13 15:17:04 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript |
Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO Tolga Tanguler - Chief Commercial Officer Pushkal Garg - CMO Jeff Poulton - CFO Christine Lindenboom - Chief Corporate Communications Officer Conference Call Participants Tazeen Ahmad - Bank of America Kostas Biliouris - BMO Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies Ritu Baral - TD Cowen Teraesa Vitelli - Scotiabank Gary Nachman - Raymond James Jessica Fye - JPMorgan Paul Matteis - Stifel Salveen Richter - Goldman Sachs Ellie Merle - UBS Mani Foroohar - Leerink Partners Luca Issi - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Fourth Quarter Full Year 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode. |
seekingalpha.com |
2025-02-13 14:31:02 |
Czytaj oryginał (ang.) |
| Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-13 12:36:37 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates |
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a year ago. |
zacks.com |
2025-02-13 12:16:35 |
Czytaj oryginał (ang.) |
| ILMN vs. ALNY: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-02-11 14:40:53 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast? |
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week. |
zacks.com |
2025-02-10 16:46:07 |
Czytaj oryginał (ang.) |
| Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-10 12:21:28 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-06 13:05:35 |
Czytaj oryginał (ang.) |
| Bet on These 4 Top-Performing Liquid Stocks for Solid Gains |
Investors can boost returns by adding these top-ranked liquid stocks, Alnylam Pharmaceuticals, Frontdoor, EverQuote and Sezzle, to their portfolios. |
zacks.com |
2025-02-03 10:41:26 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8. |
businesswire.com |
2025-01-30 10:00:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 27th |
ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024. |
zacks.com |
2025-01-27 09:06:13 |
Czytaj oryginał (ang.) |
| GILD vs. ALNY: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-23 14:41:17 |
Czytaj oryginał (ang.) |
| Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-23 12:51:15 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 21st |
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025. |
zacks.com |
2025-01-21 13:11:46 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? |
Here is how Alnylam Pharmaceuticals (ALNY) and Medpace (MEDP) have performed compared to their sector so far this year. |
zacks.com |
2025-01-21 12:41:25 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 21st |
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025. |
zacks.com |
2025-01-21 09:45:35 |
Czytaj oryginał (ang.) |
| ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals |
Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025. |
zacks.com |
2025-01-13 14:26:08 |
Czytaj oryginał (ang.) |
| Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? |
Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year. |
zacks.com |
2024-12-25 12:41:11 |
Czytaj oryginał (ang.) |
| 4 Biotech Stocks Most Wall Street Analysts Are Bullish About |
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
zacks.com |
2024-12-19 16:25:23 |
Czytaj oryginał (ang.) |
| What Makes Alnylam (ALNY) a New Buy Stock |
Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-04 15:00:35 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available. |
businesswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use |
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. |
zacks.com |
2024-11-26 12:31:36 |
Czytaj oryginał (ang.) |
| Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Based on the Company's use of a Priority Review Voucher, the FDA has set an action date goal of Mar. |
businesswire.com |
2024-11-25 09:00:00 |
Czytaj oryginał (ang.) |
| ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study |
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose. |
zacks.com |
2024-11-18 12:30:41 |
Czytaj oryginał (ang.) |
| Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These new results demonstrated that a single dose o. |
businesswire.com |
2024-11-17 11:30:00 |
Czytaj oryginał (ang.) |
| Alnylam downgraded to Underperform from Peer Perform at Wolfe Research |
Wolfe Research downgraded Alnylam to Underperform from Peer Perform, citing "unfriendly channel dynamics coupled with inability to rebate." |
https://thefly.com |
2024-11-11 18:41:30 |
Czytaj oryginał (ang.) |
| Alnylam to Webcast Presentations at Upcoming November Investor Conferences |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:30 am GMT (4:30 am ET) in London A live audio webcast of each presentat. |
businesswire.com |
2024-11-04 10:00:00 |
Czytaj oryginał (ang.) |
| Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down |
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%. |
zacks.com |
2024-11-01 12:36:13 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript |
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-10-31 13:26:04 |
Czytaj oryginał (ang.) |
| Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-10-31 13:01:28 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates |
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago. |
zacks.com |
2024-10-31 12:11:10 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. “Alnylam continued to deliver robust results commercially and clinically in the third quarter. We achieved 34% year-over-year growth, with global net product revenues of $420 million, primarily driven by our TTR business. Further with TTR, w. |
businesswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024. |
zacks.com |
2024-10-28 12:21:04 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch |
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market. |
seekingalpha.com |
2024-10-27 11:00:00 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy? |
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-24 15:05:43 |
Czytaj oryginał (ang.) |
| Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? |
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-10-23 17:01:27 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? |
Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. |
zacks.com |
2024-10-17 14:46:05 |
Czytaj oryginał (ang.) |